US › Healthcare

Exagen Inc (XGN)

US · Healthcare · Diagnostics & Research

$7.87+1.16%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$19.9M

Revenue YoY

+15.9%

Net profit

$-3.2M

EPS

$-0.13

EPS estimate

$-0.19

Net margin

-16.0%

EPS came in at -0.13 against a street estimate of -0.19 — a beat of 31.6%.

Key statistics

Market cap

$178.1M

Forward P/E

0.0

P/B

13.98

Book value

$0.51

EPS (TTM)

$-0.82

52-week high

$12.23

52-week low

$2.59

50-day MA

$6.04

200-day MA

$4.76

Beta

2.10

Analyst view

Analysts rate Exagen Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $9.86.

Shareholding

Insiders

27.75%

Institutions

44.88%

Largest institutional holders

Fund	Stake
Balyasny Asset Management LLC	3.29%
Wexford Capital LP	3.27%
Acadian Asset Management LLC	2.84%
Vanguard Capital Management, LLC	2.80%
Arnhold & S. Bleichroeder Advisers, LLC	2.53%
FourWorld Capital Management LLC	2.46%
NANO CAP NEW MILLENNIUM GROWTH FUND L P	2.41%
Silvercrest Asset Management Group LLC	2.22%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Exagen Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.